Status:
COMPLETED
Cognitive Effects of Atomoxetine in Humans: Genetic Moderators
Lead Sponsor:
Yale University
Conditions:
Addiction
Eligibility:
All Genders
21-50 years
Phase:
NA
Brief Summary
The overall goal of this study is to determine if atomoxetine treatment improves selective cognitive functions in abstinent cocaine users, compared to healthy controls. The study will also test if a f...
Detailed Description
This will be a double-blind, placebo-controlled, crossover study, with cocaine use (cocaine users vs. healthy controls) and NET AAGG4 status (L4/ L4 vs. L4/S4 or S4/ S4 genotype) as the between-subjec...
Eligibility Criteria
Inclusion
- Male and females, between the ages of 21 and 50;
- No current dependence or abuse of drugs of abuse or alcohol (except and tobacco);
- No current medical problems and normal ECG;
- For women, not pregnant as determined by pregnancy screening nor breast feeding, and using acceptable birth control methods.
Exclusion
- Current major psychiatric illnesses including mood, psychotic, or anxiety disorders;
- History of major medical illnesses; including liver diseases, heart disease, or other medical conditions that the physician investigator deems contraindicated for the subject to be in the study;
- Known allergy to Atomoxetine;
- Use of Monoamine Oxidase inhibitor within the last month (clinically Atomoxetine administration is contraindicated with or within 2 weeks of discontinuation of Monoamine oxidase inhibitor therapy).
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01498549
Start Date
December 1 2011
End Date
July 1 2013
Last Update
July 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Veterans Affairs
West Haven, Connecticut, United States, 06516